Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease

Key Findings

• ●First clinical trial of IL-18 inhibition in AOSD
• ●Favorable safety profile with early signs of efficacy at both 80mg and 160mg doses

Referenced in (1 disease)